# A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)

> **NCT04657497** · PHASE3 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 155 (actual)

## Conditions studied

- SARS-CoV-2 Infection (COVID-19)

## Interventions

- **DRUG:** FOY-305
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04657497
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2021-03-26
- **Final completion:** 2021-04-09
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2024-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657497, "A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04657497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*